Read + Share
Furstenau M, Robrecht S, Schneider C, Tausch E, et al. MRD-guided zanubrutinib, venetoclax, and obinutuzumab in relapsed CLL: primary
end point analysis from the CLL2-BZAG trial. Blood 2025;145:1282-1292.
PMID: 39883943
|
 |
|
Furstenau M, Robrecht S, Schneider C, Tausch E, et al. MRD-guided zanubrutinib, venetoclax, and obinutuzumab in relapsed CLL: primary
end point analysis from the CLL2-BZAG trial. Blood 2025;145:1282-1292.
PMID: 39883943
|
|
|
|